Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Solitary plasmacytoma of bone (SPB) is a localized tumor in the bone comprised of clonal plasma cells in the absence of other diagnostic features of multiple myeloma (MM), though patients may present with <10% clonal plasma cells in the bone marrow [ 1 ]. Most patients with SPB eventually develop overt MM, and numerous factors are associated with a shorter time to progression to active MM, including the presence of high-risk cytogenetics, abnormal serum free light chain ratio, minimal marrow involvement, and high-grade angiogenesis within the plasmacytoma [ 2 , 3 , 4 , 5 ].
Source: Blood Cancer Journal
Authors: Douglas W. Sborov, Anuj K. Mahindra, Vera J. Suman, Elisabet Esteve Manasanch, Prashant Kapoor, Tibor Kovacsovics, Cesar Rodriguez, Benjamin Parsons, Jose Eugenio Najera, Lyle Goldman, Destin Carlisle, Yujia Wen, Shira H. Dinner, Ilene A. Galinsky, LeAnne Kennedy, James Omel, Philip McCarthy, Saad Usmani, Paul G. Richardson
Institutions: University of Utah, Huntsman Cancer Institute, Scripps MD Anderson Cancer Center, Mayo Clinic, The University of Texas MD Anderson Cancer Center, City of Hope, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Gundersen Health System, Cancer Centers of Southwest Oklahoma, Ascension, Ascension Providence Hospital, University of Chicago, Atrium Health Wake Forest Baptist, Roswell Park Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
Awards: Alliance Statistics and Data Management Center, Network Lead Academic Participating Site Grant from the Roswell Park Cancer Institute, Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer Center, SWOG Network Group Operations Center of the NCTN, UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) UG1, NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care, NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1, A Lead Academic Participating Site in Oklahoma for the Design and Conduct of NCTN Clinical Trials, Wisconsin NCI Community Oncology Research Program (WiNCORP), Wake Forest NCORP Research Base, Huntsman Cancer Institute/ University of Utah Network Lead Academic Participating Site Application, Alliance for Clinical Trials in Oncology Operations Center
OpenAlex ID: W7160449753
